Amylyx Pharmaceuticals Etf Earnings Per Share
| AMLX Etf | USD 2.03 0.03 1.50% |
Amylyx Pharmaceuticals fundamentals help investors to digest information that contributes to Amylyx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Amylyx Etf. The fundamental analysis module provides a way to measure Amylyx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amylyx Pharmaceuticals etf.
Amylyx |
Amylyx Pharmaceuticals ETF Earnings Per Share Analysis
Amylyx Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Amylyx Pharmaceuticals Earnings Per Share | 0.70 X |
Most of Amylyx Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amylyx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Amylyx Pharmaceuticals has an Earnings Per Share of 0.7 times. This is much higher than that of the Pharmaceuticals family and significantly higher than that of the Health Care category. The earnings per share for all United States etfs is notably lower than that of the firm.
Amylyx Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amylyx Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Amylyx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Amylyx Pharmaceuticals by comparing valuation metrics of similar companies.Amylyx Pharmaceuticals is currently under evaluation in earnings per share as compared to similar ETFs.
Fund Asset Allocation for Amylyx Pharmaceuticals
The fund invests 50.03% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Amylyx Pharmaceuticals' investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Amylyx Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0534 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | (229.53 M) | ||||
| Shares Outstanding | 68.01 M | ||||
| Shares Owned By Insiders | 15.11 % | ||||
| Shares Owned By Institutions | 84.89 % | ||||
| Number Of Shares Shorted | 6.51 M | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 0.36 X | ||||
| Revenue | 380.79 M | ||||
| Gross Profit | (74.21 M) | ||||
| EBITDA | 39.89 M | ||||
| Net Income | 49.27 M | ||||
| Cash And Equivalents | 206.68 M | ||||
| Cash Per Share | 3.53 X | ||||
| Total Debt | 4.24 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.96 X | ||||
| Book Value Per Share | 6.52 X | ||||
| Cash Flow From Operations | 11.92 M | ||||
| Short Ratio | 2.43 X | ||||
| Earnings Per Share | 0.70 X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 4.25 | ||||
| Number Of Employees | 384 | ||||
| Beta | -0.93 | ||||
| Market Capitalization | 138.05 M | ||||
| Total Asset | 517.45 M | ||||
| Retained Earnings | (304.95 M) | ||||
| Working Capital | 382.62 M | ||||
| Net Asset | 517.45 M | ||||
| Equity Positions Weight | 50.03 % |
About Amylyx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amylyx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amylyx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amylyx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Amylyx Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amylyx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amylyx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Amylyx Etf
| 0.8 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.74 | ME | 23Andme Holding | PairCorr |
Moving against Amylyx Etf
| 0.87 | YS | YS Biopharma | PairCorr |
| 0.64 | DOMH | Dominari Holdings | PairCorr |
| 0.5 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
The ability to find closely correlated positions to Amylyx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amylyx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amylyx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amylyx Pharmaceuticals to buy it.
The correlation of Amylyx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amylyx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amylyx Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amylyx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Amylyx Pharmaceuticals Piotroski F Score and Amylyx Pharmaceuticals Altman Z Score analysis. For more information on how to buy Amylyx Etf please use our How to Invest in Amylyx Pharmaceuticals guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
The market value of Amylyx Pharmaceuticals is measured differently than its book value, which is the value of Amylyx that is recorded on the company's balance sheet. Investors also form their own opinion of Amylyx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Amylyx Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amylyx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Amylyx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amylyx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amylyx Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amylyx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.